---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-24-000006"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:21:05.561611+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LivaNova approves restructuring plan, winds down ACS unit; expects ~$110M impairment in Q4 2023

## Summary
- Board approved restructuring to focus on Cardiopulmonary and Neuromodulation; wind down ACS unit by end of 2024.
- Pre-tax restructuring charges of $15M-$20M in 2024, including $10M-$12M severance/retention and $5M-$8M other expenses.
- Triggering event in Q4 2023 leads to pre-tax non-cash impairment charge up to $110M, primarily for finite-lived intangibles.
- Some ACS products transitioned to Cardiopulmonary; LifeSPARC and Hemolung systems to be discontinued by end of 2024.
- Company to realign into two reportable segments: Cardiopulmonary and Neuromodulation.

## SEC filing metadata
- accession: 0001639691-24-000006
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 2.06, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/0001639691-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/livn-20240105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-24-000006
- JSON: https://secwatch.observer/filing/0001639691-24-000006.json
- Plain text: https://secwatch.observer/filing/0001639691-24-000006.txt

## Key facts
- Restructurings & Charges
  LivaNova PLC announced a impairment with charges of up to approximately $110 million affecting Advanced Circulatory Support ("ACS") Business Unit.
  - Type: impairment
  - Charge: up to approximately $110 million
  - Affected area: Advanced Circulatory Support ("ACS") Business Unit
  source text: the Company expects to incur a pre-tax non-cash impairment charge of up to approximately $110 million in the fourth quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/0001639691-24-000006-index.htm
- Restructurings & Charges
  LivaNova PLC announced a restructuring with charges of $15 million to $20 million affecting Advanced Circulatory Support ("ACS") Business Unit.
  - Type: restructuring
  - Charge: $15 million to $20 million
  - Affected area: Advanced Circulatory Support ("ACS") Business Unit
  source text: the Company expects to incur pre-tax restructuring charges in the range of approximately $15 million to $20 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/0001639691-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.